- Achieving Lipid Targets & Managing CV Risk: Reassessing our way with Statins
This faculty-led educational course, chaired by Dr Yassir Javaid (East Midlands Clinical Network, UK), reviews two case studies - created by Prof Kausik Ray (Imperial College London, UK) - which cover primary and secondary cardiovascular prevention in high-risk patients uncontrolled by statins.
Dr Javaid is joined by Prof Lale Tokgözoğlu (Hacettepe University, Turkey), Prof Kausik Ray and Prof Ulrich Laufs (Leipzig University, Germany) on panel. During the roundtable, the faculty discuss strategies to assess statin intolerance; CV outcomes associated with statin withdrawal; real-world data pertaining to guideline lipid targets; and emerging options for reducing CV events in high-risk patients.
This programme is supported by unrestricted educational grant by Daiichi-Sankyo. The scientific programme has not been influenced in any way.
This educational programme is not intended for UK Healthcare Professionals
In compliance with EBAC / EACCME guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
Terms & Conditions
Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable. The session ‘Achieving Lipid Targets & Managing CV Risk: Reassessing our way with Statins', is accredited by the European Board for Accreditation in Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.
Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Through an agreement between the European Board for Accreditation in Continuing Education for Health Professionals (EBAC) and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.
Instruction to Participants
There is no fee for taking part in this online learning activity. Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
To complete the course and claim certification participants must:
- Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity.
- Users must read and study the activity in its entirety before completing the post-test questions.
- Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.
- Lipid Management Specialists
- Primary Care
Upon completion of this activity, participants will be able to:
- Recall prevalence of patients who are statin uncontrolled/intolerant
- Define the additive benefit of combination treatment compared with statin intensification
- Name the non-statin LLTs offering proven CV protection
- Identifying patients with indication for novel non-statin therapy
- Initiate lipid-lowering strategies proven to lower future CV events
|Welcome and Patient Case Revisited
|Yassir Javaid Kausik (Kosh) Ray
|Managing CV Risk in Statin Intolerant or Statin Uncontrolled Patients
|Attaining Lipid Targets: How are we doing?
|Kausik (Kosh) Ray
|Reducing Major Events in High-Risk Patients: Is Statin Intensification Adequate?
|Polling Results and Conclusion
|Yassir Javaid Kausik (Kosh) Ray
Welcome and Patient Case Revisited
Duration: 9m 4s
Managing CV Risk in Statin Intolerant or Statin Uncontrolled Patients
Duration: 22m 12s
Attaining Lipid Targets: How are we doing?
Duration: 20m 18s
Reducing Major Events in High-Risk Patients: Is Statin Intensification Adequate?
Duration: 22m 57s
Polling Results and Conclusion
Duration: 10m 08s
- Identify limitations of current ablation technologies
- Recall the advantages of pulse field ablation over other technologies
- Summarise the design, efficacy and safety findings of relevant clinical trial data evaluating the efficacy and safety of pulse field ablation technology
- Compare different PFA systems and emerging technologies
- Evaluate the evolving landscape of pulse field ablation technologies
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists